The Australia Apheresis Market was valued at $2.68 Million in 2026 and projected to reach to $3.5 Million by 2031, representing a compound annual growth rate of 9.3%. Australia's apheresis market is positioned for sustained expansion through 2031, driven by demographic shifts toward an aging population with increased prevalence of chronic diseases requiring apheresis interventions.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Australia's apheresis market is valued at $2.68 billion in 2026 and is projected to reach $3.50 billion by 2031, representing a strong 9.3% CAGR that outpaces the global average of 7.9%.
Australia's well-developed healthcare system and increasing investment in medical technologies are driving widespread adoption of apheresis equipment across hospitals, blood banks, and specialty clinics.
Growing incidence of blood disorders, autoimmune diseases, and cancer in Australia is fueling demand for therapeutic apheresis procedures and diagnostic applications in clinical settings.
Australia's TGA approval pathways and supportive regulatory environment are enabling rapid commercialization of advanced apheresis technologies and novel treatment protocols.
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | CHINA (Technology) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 7.9% from 2026 to 2031 |
| Largest Segment | BLOOD COLLECTION CENTERS AND BLOOD COMPONENT PROVIDERS (End User) |
| Market Size Base Year (Billions) | ~USD 3.02 (2026) |
| Revenue Forecast (Billions) | ~USD 4.41 (2031) |
| Segments Covered | Technology, End User, Type, Application, Product, Disease Type, Procedure, Product 2021–2029 |
8 segment dimensions are covered across the global market.
| Segment | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| BLOOD COLLECTION CENTERS AND BLOOD COMPONENT PROVIDERS | 24.56 | 26.29 | 28.18 | 30.24 | 32.48 | 34.92 | 37.58 | 40.47 | 7.5 |
| HOSPITALS AND TRANSFUSION CENTERS | 12.66 | 13.7 | 14.84 | 16.1 | 17.47 | 18.98 | 20.64 | 22.46 | 8.6 |
| OTHER END USERS | 2 | 2.12 | 2.25 | 2.39 | 2.54 | 2.7 | 2.87 | 3.06 | 6.4 |
| TOTAL | 39.22 | 42.11 | 45.28 | 48.73 | 52.49 | 56.6 | 61.09 | 66 | 7.8 |
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| FRESENIUS MEDICAL CARE | Germany | Public Company | Outpatient dialysis services (Care Delivery),Hemodialysis machines, consumables, and water systems,Peritoneal dialysis cyclers and solutions, |
| INFOMED SA | Australia | Private Company | Microcat EPC and parts ordering (EPC, PartsBridge, Market, CRM),Superservice suite (Menus, Triage, Connect, Register),E-commerce platforms (SimplePart, INFODRIVE), |
| HAIER BIOMEDICAL | China | Public Company | Low temperature storage (ULT, pharmacy, blood bank, plasma, vaccine, cold/freezer rooms, transport),Laboratory equipment (incubators, biosafety cabinets, clean benches, sterilization, centrifuges, analytical instruments, consumables),Intelligent automation and RFID pharmacy solutions, |
| JAFRON BIOMEDICAL CO., LTD. | China | Public Company | HA series disposable hemoperfusion cartridges,BS series plasma bilirubin adsorption columns,Blood purification machines and related equipment, |
Fresenius Medical Care is a German public company founded in 1996 that operates as a global healthcare provider with over 108,000 employees. The company specializes in dialysis products and services for patients with chronic kidney failure.
Infomed SA is an Australian private company established in 1987 with 300 employees operating in the medical device and healthcare sector.
Haier Biomedical is a Chinese public company established in 2005 with 2,945 employees that manufactures biomedical equipment and laboratory instruments.
Jafron Biomedical Co., Ltd. is a Chinese public company founded in 1989 with 2,301 employees that develops and manufactures medical devices and biotechnology products.
Australia's apheresis market was valued at $2.68 billion in 2026 and is expected to reach $3.50 billion by 2031.
Australia's apheresis market is growing at a compound annual growth rate (CAGR) of 9.3% from 2026 to 2031.
Key drivers include rising prevalence of blood disorders, increasing demand for plasma-derived therapies, enhanced reimbursement frameworks, and Australia's aging population requiring advanced therapeutic interventions.
Australia's apheresis market is growing at 9.3% CAGR, outpacing the global market growth rate of 7.9%, reflecting strong regional demand and healthcare investment.
Australia's established regulatory oversight, robust blood collection networks, and healthcare system prioritizing innovative treatment modalities create a favorable environment for apheresis technology adoption and market growth.
This study involved the extensive use of both primary and secondary sources. The research process involved examining various factors affecting the industry to identify segmentation types, industry trends, key players, the competitive landscape, key market dynamics, and key players' strategies.
The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, Companies House documents, investor presentations, and SEC filings. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the apheresis market. It was also used to obtain important information about key players, market classification & segmentation according to industry trends, down to the bottom level, and key developments from market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
In the primary research process, various sources from both the supply & demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations in the apheresis market. The primary sources from the demand side include medical OEMs, medical device ISOs, and service providers, among others. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights into key industry trends & key market dynamics.

Note 1: C-level primaries include CEOs, COOs, CTOs, and VPs.
Note 2: Others include sales, marketing, and product managers.
Note 3: Companies are classified into tiers based on their total revenue. As of 2025, Tier 1 = >USD 2 billion, Tier 2 = USD 50 million to USD 2 billion, and Tier 3 = <USD 50 million.
To know about the assumptions considered for the study, download the pdf brochure
In this report, the global apheresis market size was determined using revenue share analysis of leading players. For this purpose, key market players were identified, and their revenues from the apheresis business were determined using insights gathered during the primary and secondary research phases. Secondary research included the study of the annual and financial reports of the top market players. In contrast, primary research included extensive interviews with key opinion leaders, including CEOs, directors, and marketing executives.
To calculate the global market value, segmental revenues were derived from the revenue mapping of major solution/service providers. This process involves the following steps:

After arriving at the overall market size through the market size estimation process explained above, the global apheresis market was segmented and subsegmented. Data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides. Additionally, the apheresis market was validated using both top-down and bottom-up approaches.
Apheresis is a medical technology and extracorporeal blood separation procedure in which whole blood is withdrawn from a donor or patient and processed through a device that separates specific blood components. The desired component is collected or treated, while the remaining blood components are returned to the individual. The process primarily uses centrifugation or membrane filtration to separate blood components.
Apheresis encompasses both donor and therapeutic procedures and is widely used in transfusion medicine, hematology, oncology, nephrology, neurology, and immunology for blood component collection and the treatment of various disorders, including autoimmune diseases, hematologic conditions, and metabolic disorders.
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the present global apheresis market report:
Product Analysis
Company Information
Geographic Analysis
Full forecast, segment splits, and company analysis for all Apheresis Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report